Surfactant Protein D Human ELISA

Catalog number: RD194059101
Brand: BioVendor
Packing: 96 wells
Price: € 561.00
Expected delivery time: 7 days
Quantity:

Product specifications for - Surfactant Protein D Human ELISA

Overview: 
Product group: Assays
Category: ELISA / EIA
Properties: 
Assay Sensitivity: 0,01 ng/ml
Assay Precision: Inter assay: n = 5, CV = 3,1%, Intra assay: n = 8, CV = 2,2%,
Assay Sample Type: serum, plasma (EDTA, citrate, heparin), bronchoalveolar lavage fluid and amniotic fluid
Assay Time: The total assay time is less than 5 hours
Assay Detection Range: 1,56 - 100 ng/ml
  IVD Certification
UNSPSC: 41116158
Storage instructions: Store the complete kit at 2-8-¦C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Scientific information: 
Scientific info: Human Surfactant Protein D (SP-D) is a member of the collageneous subfamily of glycoproteins and calcium-dependent lectins (collectins). SP-D is a homotrimeric protein consisting of three 43kDa units that are bonded at their Ntermini. Most preparations of SP-D contain predominantly dodecamers (four trimeric subunits), but also higher multimers have been observed. Each unit consists of at least four discrete structural domains: a short N-terminal domain, a relatively long collagenous domain, a short amphipathic connecting peptide, and a C-terminal, C- type lectin carbohydrate recognition domain (CRD). SP-D is synthesized and secreted by two types of non-ciliated epithelial cells in the peripheral airway, alveolar type II cells and Clara cells. It is also expressed by various epithelial cells in the gastrointestinal and genitourinary tracts and placenta. In the lungs, SP-D participates in the innate response to inhaled microorganisms and organic antigens. SP-D acts by aggregating bacteria and viruses, leukocyte function and stimulating an allergenic response. SP-D binds to the surface glycoconjugates of various microorganisms (eg, influenza virus, HIV, HSV, RSV, Mycoplasma pneumoniae) and the oligosaccharides associated with the surface of numerous organic antigens and enhances their phagocytosis. Studies have shown that SP-D binds to T cells, thus inhibiting their proliferation. SP-D also binds with inflammatory ligands via protein-protein and protein-carbohydrate interactions that are effective in reducing specific inflammation. In addition, SP-D binds to apoptotic cells and stimulates their phagocytosis by macrophages governed by mechanisms dependent and CD91 calreticulin. Given that SP-D together with SP-A affects the reactivity of immune cells, their presence in the endometrium and placenta plays an important role in protection against bacteria and toxins during pregnancy. Reduced levels of all components of pulmonary surfactant, including SP-D, has been linked to premature birth. Disturbance of pulmonary surfactant is in many cases the reason for collapse of the lungs and is also associated with many pulmonary diseases. All types of chronic lung disease is characterized by pathologically altered levels in lung tissue (fibrosis and emphysema). Studies have shown that expression of SP-D is associated with many pulmonary diseases: cystic fibrosis, acute interstitial pneumonia (ARDS), chronic obstructive pulmonary disease, asthma, bronchopulmonary dysplasia, alveolar capillary dysplasia, alveolar proteinase and tuberculosis. Clinical application and areas of investigation: Cystic fibrosis, Acute interstitial pneumonia (ARDS), Chronic obstructive pulmonary disease, Asthma, Bronchopulmonary dysplasia, Alveolar capillary dysplasia and alveolar proteinase, Immune response, infection and inflammation
Additional information: 
Synonyms: RD194059101; BioVendor
Alexis NE, Lay JC, Haczku A, Gong H, Linn W, Hazucha MJ, Harris B, Tal-Singer R, Peden DB. Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers. Environ Health Perspect. 2008 Jun,116 (6):799-805 Read more
Anderson JT, Zeng M, Li Q, Stapley R, Moore DR 2nd, Chenna B, Fineberg N, Zmijewski J, Eltoum IE, Siegal GP, Gaggar A, Barnes S, Velu SE, Thannickal VJ, Abraham E, Patel RP, Lancaster JR Jr, Chaplin DD, Dransfield MT, Deshane JS. Elevated levels of NO are localized to distal airways in asthma. Free Radic Biol Med. 2011 Jun 1,50 (11):1679-88 Read more
Aul R, Armstrong J, Duvoix A, Lomas D, Hayes B, Miller BE, Jagger C, Singh D. Inhaled LPS challenges in smokers: a study of pulmonary and systemic effects. Br J Clin Pharmacol. 2012 Dec,74 (6):1023-32 Read more
Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung . 2009 Jul,26 (2):155-61 Read more
Bejvl I, Weseslindtner L, Strassl R, Jaksch P, Kundi M, Klepetko W, Puchhammer-Stockl E. Analysis of plasma surfactant protein D levels in lung transplant recipients. Transpl Infect Dis. 2013 Dec,15 (6):645-51 Read more
Bonlokke JH, Riddervold IS, Gronborg TK, Skogstrand K, Hougaard DM, Barregard L, Sigsgaard T. Systemic effects of wood smoke in a short-term experimental exposure study of atopic volunteers. J Occup Environ Med. 2014 Feb,56 (2):177-83 Read more
Bratcher PE, Gaggar A. Factors influencing the measurement of plasma/serum surfactant protein d levels by ELISA. PLoS One. 2014,9 (11):e111466 Read more
Bullone M, de Lagarde M, Vargas A, Lavoie JP. Serum Surfactant Protein D and Haptoglobin as Potential Biomarkers for Inflammatory Airway Disease in Horses. J Vet Intern Med. 2015 Nov-Dec,29 (6):1707-11 Read more
Daneshzadeh Tabrizi R, Bernard A, Thommen AM, De Winter F, Oppliger A, Hilfiker S, Tschopp A, Hotz P. Surfactant protein-D and exposure to bioaerosols in wastewater and garbage workers. Int Arch Occup Environ Health. 2010 Dec,83 (8):879-86 Read more
Delgado C, Krotzsch E, Jimenez-Alvarez LA, Ramirez-Martinez G, Marquez-Garcia JE, Cruz-Lagunas A, Moran J, Hernandez C, Sierra-Vargas P, Avila-Moreno F, Becerril C, Montano M, Banales-Mendez JL, Zuniga J, Buendia-Roldan I. Serum surfactant protein D (SP-D) is a prognostic marker of poor outcome in patients with A/H1N1 virus infection. Lung. 2015 Feb,193 (1):25-30 Read more